Alector is a biotechnology company focused on developing novel therapeutics for neurodegenerative diseases. Their approach, termed immuno-neurology, utilizes insights from immunology, neurology, and human genetics to create therapies that harness the body's innate healing potential. Alector is driven by the mission to transform the treatment of conditions such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). They emphasize a culture of curiosity and collaboration, aiming to provide first-in-class therapeutics that make a profound impact on patients' lives.
Biotechnology β’ Neurodegenerative disease β’ Neurodegeneration β’ Immuno-neurology
51 - 200 employees
Founded 2013
𧬠Biotechnology
βοΈ Healthcare Insurance
π Pharmaceuticals
π° $133M Series E on 2018-07
November 13
Drive health economics and outcomes research strategies at Alector.
πΊπΈ United States β Remote
π΅ $261k - $282k / year
π° $133M Series E on 2018-07
β° Full Time
π΄ Lead
π Director
π¦ H1B Visa Sponsor